| RFA | Multi-Scale Models Bridging Levels of Analysis in Aging and Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R01 Clinical Trial Not Allowed) | Jun. 14, 2024 | NIA | Amanda DiBattista | Jun | New |
| IGNITE | Development and Validation of Model Systems to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed) (PAR-21-123) | Jun. 24, 2024 | NINDS | Becky Roof | Jun, Oct, Feb | Resub. |
| BPN | Biologic-Based Drug Discovery and Development for Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional) (PAR-21-163, PAR-21-233) | Aug. 20, 2024 | NINDS, NEI, NIA, NIAAA, NIBIB, NICHD, NIDCR, NIDA, NIMH, NCCIH, OBSSR | Lauren Friedman, Kelly Sheppard, Melissa Ghim, Enrique Michelotti, Thomas N. Greenwell, Neeraj Agarwal, Paek Lee, Qi-Ying Liu, Jason Sousa, Hye-Sook Kim, Tony Gover, Shreaya Chakroborty | Aug, Feb | Resub. |
| BRAIN Initiative: Theories, Models and Methods for Analysis of Complex Data from the Brain (R01 Clinical Trial Not Allowed)| Sep. 13, 2024 | NIDA, NEI, NIA, NIAAA, NIBIB, NICHD, NIDCD, NIMH, NINDS, NCCIH, OBSSR | Susan N. Wright, PhD | | |
|
| PAR | Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed) | Sep. 14, 2024 | NCI | Lokesh Agrawal, Abhi Rao | Jan, Jun, Sept | Resub. |
| PAR | Investigating Distinct and Overlapping Mechanisms in TDP-43 Proteinopathies, Including in LATE, FTD, and Other ADRDs (PAR-24-148) | Oct. 5, 2024 | NIA, NINDS | Linda McGavern, Tong Li | Jun, Oct | Resub. |
| PAR | Mechanistic Investigations into ADRD Multiple Etiology Dementias (R01 - Clinical Trial Not Allowed) | Oct. 5, 2024 | NIA, NINDS | Linda McGavern, Austin YANG | Jun, Oct | Resub. |
| PAR | Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed) | Oct. 11, 2024 | NINDS | Chris Boshoff | Dec, Feb Jun | Resub. |
| IGNITE | Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed) | Oct. 22, 2024 | NINDS, NCCIH | Becky Roof, Craig Hopp, Shelley Carow | Jun, Oct, Feb | Resub. |
| RFA | Development and Validation of Human Cellular Models for Alzheimer’s Disease-Related Dementias (R01 Clinical Trial Not Allowed) (RFA-NS-24-032) | Oct. 22, 2024 | NIA, NINDS | Linda McGavern, Frank Shewmaker, Amanda DiBattista | Jun, Oct | Resub. |
| IGNITE | Neurotherapeutic Agent Characterization and In Vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed) (PAR-21-122) | Oct. 22, 2024 | NINDS | Becky Roof | June, Oct, Feb | Resub. |
| PAR | Advancing Methods for Safe, Noninvasive, Real Time Assessment of Placenta Development and Function Across Pregnancy (R01, PAR-22-237) (R21, PAR-22-236) | Nov. 6, 2024 | NICHD, ORWH | David Weinberg, Elena K Gorodetsky | Feb, Oct | Resub. |
| NOSI | Investigation of Biomolecular Condensates in Aging and Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (NOT-AG-23-037) | Nov. 13, 2024 | NIA | Paul Barrett | Mar, Jul, Nov | Resub. |
| PAR | Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01, PAR-19-070) (R21, PAR-19-071), Notice to Specify High-Priority Research Topic (NOT-AG-18-047, NOT-AG-18-046, NOT-AG-18-052, NOT-AG-18-048) | Nov. 13, 2024 | NIA | Sanoj K. Suneja, Roderick Corriveau | Mar, Jul, Nov | Resub. |
| PAR | Research on Current Topics in Alzheimer’s Disease and Its Related Dementias (R01 Clinical Trial Optional) (PAR-22-093, PAR-22-094) | Nov. 13, 2024 | NIA, NINDS | Sanoj K. Suneja, Roderick Corriveau | Mar, Jul, Nov | Resub. |
| NOSI | Investigation of Biomolecular Condensates in Aging and Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (NOT-AG-23-037) | Nov. 13, 2024 | NIA | Paul Barrett | Mar, Jul, Nov | Resub. |
| Stimulants and HIV: Addressing Contemporary and Recurring Epidemics (R61/R33 – Clinical Trial Required) | Nov. 13, 2024 | NIDA | Richard A. Jenkins PhD | | |
| NIDA REI: Racial Equity Visionary Award Program for Research on Substance Use and Racial Equity (DP1 Clinical Trial Optional) | Nov. 15, 2024 | NIDA | Minnjuan Flournoy Floyd, PhD | | |
| RFA | Interplay of Autophagy Regulated Cell Death and HIV Pathogenesis in Substance Use Disorders (R01, RFA-DA-25-009) (R21, RFA-DA-25-010) | Nov. 15, 2024 | NIDA | Shang-Yi Anne Tsai | Nov | New |
| NIDA REI: Research on Neurocognitive Mechanisms Underlying the Impact of Structural Racism on the Substance Use Trajectory (R61/R33 Clinical Trial Optional) | Nov. 15, 2024 | NIDA | Vani Pariyadath, PhD | | |
| NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities in Underserved Racial and/or Ethnic Populations (R01 Clinical Trial Optional) | Nov. 15, 2024 (R01 & R34) | NIDA | Sheba K. Dunston, EdD | | |
| NIDA REI: Addressing Racial Equity in Substance Use and Addiction Outcomes Through Community-Engaged Research at Minority Serving Institutions (R01 Clinical Trial Optional) | Nov. 15, 2024 | NIDA | Alexa Romberg, PhD | | |
| NIDA REI: Research at Minority Serving Institutions on Neurocognitive Mechanisms Underlying the Impact of Structural Racism on the Substance Use Trajectory (R61/R33 Clinical Trial Optional) | Nov. 15, 2024 | NIDA | Vani Pariyadath, PhD | | |
| NIDA REI: Racial Equity Visionary Award Program for Research at Minority Serving Institutions on Substance Use and Racial Equity (DP1 Clinical Trial Optional) | Nov. 15, 2024 | NIDA | Minnjuan Flournoy Floyd, PhD | | |
| Accelerating the Pace of Drug Abuse Research Using Existing Data (R01 Clinical Trial Optional) | Nov. 16, 2024 | NIDA | Marsha F. Lopez, PhD, MH.S | | |
| Chemical Countermeasures Research Program (CCRP) Initiative: Basic Research on The Deleterious Effects of Acute Exposure to Ultra-Potent Synthetic (UPS) Opioids (R01 Clinical Trial Not Allowed) | Nov. 20, 2024 | NIDA, NIAID | Kiran Vemuri, PhD
Dave Yeung, PhD | | |
| PAR | Global Brain and Nervous System Disorders Research Across the Lifespan (R01, PAR-22-097, PAR-22-098) | Dec. 10, 2024 | | | | |
| NOSI | Bold New Bioengineering Research for Heart, Lung, Blood and Sleep Disorders and Diseases (NOT-HL-21-024) | Jan. 8, 2025 | NHLBI | Narasimhan Danthi | Standard | Resub. |
| PAR | Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional) (PAR-21-290) | Jan. 8, 2025 | NCI | Solita Chiayeng Wang | Oct, Feb, Jun | Resub. |
| PAS | Stimulating Hematology Investigation: New Endeavors (SHINE) (R01) (PAS-22-096) (NOT-DK-16-007) | Jan. 8, 2025 | NIDDK, NLLBI, NIA | Shilpa Hattangad, Cindy N. Roy, Brian Bai, Rebecca Fuldner, John P. Williams | Feb, Jun, Oct | Resub. |
| PAR | Bioengineering Partnerships with Industry (U01 Clinical Trial Optional) (PAR-22-123) | Jan. 8, 2025 | NIBIB, NCI, NEI, NIA | Guoying Liu, Miguel R. Ossandon, Leonid Tsap, Tony Douglas Gover | May, Sep | Resub. |
| PA | Joint NINDS/NIMH Exploratory Neuroscience Research Grant (R21, PA-21-219) | Jan. 8,2025 | NINDS/NIMH | | | |
| PAR | NINDS Efficacy Clinical Trials (UG3/UH3, PAR-21-237) | Jan. 9,2025 | NINDS | | | |
|
Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R41/R42 Clinical Trial Optional) | Feb. 15, 2025 (R41/R42 and R43/44) | NIDA | Leonardo Angelone, PhD
Tam Nguyen, PhD | | |
| PAR | Clinical Trial Readiness for Rare Neurological and Neuromuscular Diseases (U01, PAR-22-184) | Feb. 20, 2025 | NINDS | | | |
| PAR | NINDS Exploratory Clinical Trials (UG3/UH3, PAR-22-142) | Mar. 11, 2025 | NINDS | | | |
| Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R34 Clinical Trial optional) | Mar. 20, 2025 (R01) | NIDA | Minnjuan Flournoy Floyd, PhD |
| |
| PAR | Development of Biomarkers or Biomarker Signatures for Neurological and Neuromuscular Disorders (R61/R33 Clinical Trial Optional) (PAR-22-089) | May 8, 2025 | NIA, NINDS | Carol Taylor-Burds, Yuan Luo | Jun, Feb | Resub. |
| PAR | Technology Development Research for Establishing Feasibility and Proof of Concept (R21 - Clinical Trial Not Allowed) (PAR-22-126)/a> | May 8, 2025 | NIGMS, NCI, NIA | Alvin Yeh, Kadir Aslan, Piotr Grodzinski, Miguel R. Ossandon, Leonid Tsap | Feb, Jun, Oct | Resub. |
| PAR | Focused Technology Research and Development (R01 Clinical Trial Not Allowed) (PAR-22-127) | May 8, 2025 | NIGMS, NCI, NIA | Alvin Yeh, Kadir Aslan, Piotr Grodzinski, Miguel R. Ossandon, Leonid Tsap | Feb, Jun, Oct | Resub. |
| PAR | Prospective Observational Comparative Effectiveness Research in Clinical Neurosciences (UG3/UH3, PAR-22-076) | May 8, 2025 | | | | |
| Focused Technology Research and Development (R01 - Clinical Trial Not Allowed) | May 8, 2025 | | | | |
| PAR | Industrialization and Translation of Extracellular Vesicles for use in Regenerative Medicine (UT1/UT2) Clinical Trial Not Allowed (PAR-23-268) | Jun. 7, 2025 | NCATS | Christine Happel, Meena Rajagopal | Jun | Resub. |
| NOSI | Utilization of Cohorts and Prospective Study Designs for Liquid Biopsy Assay Validation for Early Detection of Cancers | Jul. 2, 2025 | NCI | Matthew Young, Leah E. Mechanic, Xing-Jian Lou | Multiple PARs | |
| Avenir Award Program for Chemistry and Pharmacology of Substance Use Disorders (DP1- Clinical Trial Not Allowed) | Aug. 08, 2025 | NIDA | Sam Ananthan, PhD | | |
| Ex Vivo Models for Studies at the Intersection of HIV and Poly-Substance Use (R01 Clinical Trial Not Allowed) | Aug. 14, 2025 | NIDA | Da-Yu Wu, PhD | | |
| Microglial Pathophysiology in Comorbid Substance Use Disorder (SUD) and HIV (R61/R33 Clinical Trial Not Allowed) | Aug. 14, 2025 | NIDA | Tristan McClure-Begley, PhD | | |
| RFA | Exploratory studies to investigate mechanisms of HIV infection, replication, latency, and/or pathogenesis in the context of substance use disorders (R01 Clinical Trial Not Allowed)Exploratory studies to investigate mechanisms of HIV infection, replication, latency, and/or pathogenesis in the context of substance use disorders (R01 Clinical Trial Not Allowed) | August 15, 2025 | NIDA | Shang-Yi Anne Tsai, Kathleen Borgmann | Aug | Resub. |
| PAS | Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R43/R44 Clinical Trial Optional) | Sep. 6, 2025 | NIA, NINDS | Zane Martin, Michael-David ARR Kerns, Annette Gilchrist | Sep, Jan, Apr | Resub. |
| PAR | Precision Approaches in Radiation Synthetic Combinations (PAIRS, R21 Clinical Trial Optional)https://grants.nih.gov/grants/guide/pa-files/PAR-22-199.html | Sep. 7, 2025 | NCI | | | |
| NOSI | Studies of Cellular/Molecular Pathobiological Mechanisms of Lung Diseases Using Human 3-Dimensional Cellular Systems (R01) | Sep. 8, 2025 | NHLBI | Qing Lu | Standard | Resub. |
| PAR | Bioengineering Research Grants (BRG) (R01 Clinical Trial Not Allowed) | Sep. 8, 2025 | NCI, NEI, NIAMS, NIDCD, NIDCR, NINDS | Rao Divi, David Jonathan Miller, Miguel R. Ossandon, Toyin Ajisafe, Tony Douglas Gover, Orlando Lopez, Linda Bambrick, Xincheng (Ted) Zheng, Nancy Freeman | Feb, Jun, Oct | Resub. |
| Studies of Cellular/Molecular Pathobiological Mechanisms of Lung Diseases Using Human 3-Dimensional Cellular Systems (R01) | Sep. 8, 2025 | NHLBI | Qing Lu, Ph.D. | Standard | Resub. allowed |
| RNA Delivery Technologies to Allow Specific Tissue Target Homing (RNA-DASH) | Jan. 6. 2027 | NIAID, NCATS, NCI | Michael Minnicozzi, PhD
Kien Nguyen, Ph
Roger Ptak, PhD
Xing-Jian Lou, PhD
Philip J. ("Pj") Brooks, PhD | Standard | Resub. not applicable |
| NOSI | Advancing Research for Tickborne Diseases (TBDs) | Jan. 8, 2026 | NIAID, NIAMS, NIMH, NINDS | Samuel Perdue, Su-Yau Mao, Sarah H. Lisanby, William Daley | | |
| PAR | NIH SIREN Neurologic Clinical Trials (UG3/UH3 - Clinical Trial Required) | Mar. 7, 2026 | NINDS | | | |
| PAR | Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U01 Clinical Trial Optional) | Jun. 23, 2026 | NINDS | Carol Taylor-Burds | Mar, Jun, Feb | Resub. |
| PAR | Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U01 Clinical Trial Optional) (PAR-24-097, PAR-24-096) | Jun. 23, 2026 | NINDS | Carol Taylor-Burds | Marc, Jun, Feb | Resub. |
| RFA | BRAIN Initiative: Production and distribution facilities for brain cell type-specific access reagents (U24, RFA-MH-25-105) | Jul. 2, 2026 | | | | |
| BPN | Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional) | Aug. 19, 2026 | NINDS, NEI, NIA, NIAAA, NIDCR, NIDA, NIMH, NCCIH, OBSSR | Charles Cywin, Enrique Michelotti, Lorenzo M. Refolo, Qi-Ying Liu, Zhaoxia Ren, Patrick C. Still, Melissa Ghim, Paek Lee, Elena Koustova | Feb, Jul, Jan | Resub. |
| NOSI | Neuropathogenesis of CNS Complications Associated with HIV | Sep. 8, 2026 | NIMH, NINDS | Vasudev R Raom, William Daley | | |
| NOSI | Clinical Studies of CNS Complications in People with HIV | Sep. 8, 2026 | NIMH, NINDS | Vasudev R Raom, William Daley | | |
| NOSI | Eradication of HIV-1 from Central Nervous System Reservoirs | Sep. 9, 2026 | NIMH, NINDS | Jeymohan Joseph, William Daley | | |
| PAR | NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional) | Nov. 20, 2026 | NINDS | Scott Janis | Marc, Jun, Oct | Resub. |
| NOSI | RNA Delivery Technologies to Allow Specific Tissue Target Homing (RNA-DASH) | Jan. 6, 2027 | NIAID, NCATS, NCI | Michael Minnicozzi, Kien Nguyen, Roger Ptak, Xing-Jian Lou, Philip J. ("Pj") Brooks | Sept, Jan, Ap | Resub. |
| PAR | Multidisciplinary Studies of HIV/AIDS and Aging (R01 Clinical Trial Optional) (PAR-24-091, PAR-24-092) | Jan. 8, 2027 | NIA, NIAAA, NIAMS, NIDCR, NIDDK, NIDA, NIMH, NINDS, NCI, ORWH | Ann Namkung, Kendall J. Bryant, Vasudev R. Rao, Richard A Jenkins, Heiyoung Park, William Daley, Geraldina Dominguez, Hongen Yin, Elizabeth Anne Barr, Peter J Perrin | May, Sep, Jan | Resub. |
| RFA | BRAIN Initiative: Development and Validation of Novel Tools to Probe Cell-Specific and Circuit-Specific Processes in the Brain (R01 Clinical Trial Not Allowed) | Feb. 9, 2027 | | | | |
| CAREER DEVELOPMENT | | | | | | |
| PAR | Support for Research Excellence – First Independent Research (SuRE-First) Award (R16, PAR-24-145) | Jan. 8, 2027 | | | | |
| RFA | Building Interdisciplinary Research Careers in Women's Health (BIRCWH) (K12, RFA-OD-24-013) | May 29, 2026 | | | | |
| RFA | NIMH Biobehavioral Research Awards for Innovative New Scientists (NIMH BRAINS) (R01, RFA-MH-22-185) | Jun. 21, 2025 | | | | |
| RACIAL EQUITY INITIATIVE | | | | | | |
| PAR-21-290 | Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional) | Jan. 08, 2025 | NCI | | | |
| Focused Technology Research and Development (R01 - Clinical Trial Not Allowed)/a> | May 8, 2025 | | | | |
American Society for Intercellular Communication